CDT Equity (CDT) Non-Current Deffered Revenue (2022 - 2024)
CDT Equity's (CDT) quarterly Non-Current Deffered Revenue came in at $5.7 million in Q2 2024, little changed on a QoQ basis from $5.7 million in Q4 2023.
CDT Equity (CDT) Non-Current Deffered Revenue (2022 - 2024) Analysis & Trends
CDT Equity (CDT) has 3 years of Non-Current Deffered Revenue data on file, last reported at $5.7 million in Q2 2024.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $5.7 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $5.7 million (changed N/A YoY) and the FY2023 annual result came in at $5.7 million, up 40.53% from the prior year.
- Non-Current Deffered Revenue held at $5.7 million in Q2 2024, from $5.7 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $5.7 million in Q4 2023 to a low of $2.7 million in Q3 2023.
- A 3-year average of $4.4 million and a median of $4.1 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- The widest YoY moves for Non-Current Deffered Revenue: up 40.53% in 2023, down 29.03% in 2023.
- Tracing CDT's Non-Current Deffered Revenue over 3 years: stood at $4.1 million in 2022, then surged by 40.53% to $5.7 million in 2023, then changed by 0.0% to $5.7 million in 2024.
- The last three Non-Current Deffered Revenue figures came in at $5.7 million (Q2 2024), $5.7 million (Q4 2023), and $2.7 million (Q3 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 5.74 Mn |
| Dec 31, 2023 | 5.74 Mn |
| Sep 30, 2023 | 2.67 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Sep 30, 2022 | 3.76 Mn |